PRESS-RELEASE filed May 6, 2026 at 16:01 ET
MannKind reported Q1 2026 GAAP EPS of -$0.05, a 600% miss vs. consensus of $0.01, and revenue of $90.2M, 14.4% below the $105.3M estimate. The miss was driven by a 116% surge in SG&A from Furoscix expansion and R&D ramp-up, despite a 15% YoY revenue increase. Pipeline catalysts (Afrezza pediatric PDUFA May 29, Furoscix ReadyFlow PDUFA July 26) provide optionality but do not offset the earnings disappointment.